BSXC Stock Overview
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Boston Scientific Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$68.50 |
| 52 Week High | US$69.00 |
| 52 Week Low | US$45.74 |
| Beta | 0.79 |
| 1 Month Change | 9.46% |
| 3 Month Change | 21.50% |
| 1 Year Change | 46.09% |
| 3 Year Change | 89.02% |
| 5 Year Change | n/a |
| Change since IPO | 88.39% |
Recent News & Updates
Recent updates
Shareholder Returns
| BSXC | AT Medical Equipment | AT Market | |
|---|---|---|---|
| 7D | 7.0% | -0.2% | 0.7% |
| 1Y | 46.1% | -6.2% | 2.7% |
Return vs Industry: BSXC exceeded the Austrian Medical Equipment industry which returned 2.1% over the past year.
Return vs Market: BSXC exceeded the Austrian Market which returned 3.7% over the past year.
Price Volatility
| BSXC volatility | |
|---|---|
| BSXC Average Weekly Movement | 2.6% |
| Medical Equipment Industry Average Movement | 5.8% |
| Market Average Movement | 3.4% |
| 10% most volatile stocks in AT Market | 5.2% |
| 10% least volatile stocks in AT Market | 1.5% |
Stable Share Price: BSXC has not had significant price volatility in the past 3 months.
Volatility Over Time: BSXC's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1979 | 48,000 | Mike Mahoney | www.bostonscientific.com |
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.
Boston Scientific Corporation Fundamentals Summary
| BSXC fundamental statistics | |
|---|---|
| Market cap | €99.90b |
| Earnings (TTM) | €1.65b |
| Revenue (TTM) | €13.71b |
61.0x
P/E Ratio7.3x
P/S RatioIs BSXC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BSXC income statement (TTM) | |
|---|---|
| Revenue | US$14.71b |
| Cost of Revenue | US$4.55b |
| Gross Profit | US$10.16b |
| Other Expenses | US$8.39b |
| Earnings | US$1.77b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.20 |
| Gross Margin | 69.05% |
| Net Profit Margin | 12.00% |
| Debt/Equity Ratio | 49.0% |
How did BSXC perform over the long term?
See historical performance and comparison